why choose us

First received: December 13, 2022

Clinical Trial: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Relapsed/Refractory Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Brief Summary: A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma.The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).

Read more